Expansion of the Contract Synthesis Business for Nucleic Acid Medicines
First written in FY2016. 20 of 40 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-07-28.
0 other companies' latest entry also says "Cited as achieved".
- FY2026AdvancedAnnual report
「In the Life Sciences business, we established scale-up technology for nucleic acid process materials and began full-scale production at the new plant. In addition, a new processing plant in North America is expected to begin operations in fiscal 2026.」
For nucleic acid materials, scale-up technology was established and full-scale production began at the new plant. Operations at the new processing plant in North America are also expected to begin in fiscal 2026. - FY2026-H1AdvancedAnnual report
「In the nucleic acid contract manufacturing field, projects involving major diseases moved from the clinical stage to the commercialisation stage, leading to improved earnings.」
In nucleic acid drug contract manufacturing, projects involving major diseases moved from the clinical stage to the commercialisation stage, entering a phase of improving earnings. - FY2025AdvancedAnnual report
「At our Tohoku facility, which manufactures NittoPhaseTM polymer beads for nucleic acid synthesis, one of the HumanFlagsTM-certified products, we completed construction of the first factory in our group to achieve zero CO2 emissions by maximising the use of self-generated renewable energy, and began production operations during the current consolidated fiscal year.」
As a foundation for increasing NittoPhase production, the factory at the Tohoku facility, which achieves zero CO2 emissions, was completed and began production operations. - FY2025-H1AdvancedAnnual report
「In nucleic acid contract manufacturing, we began producing projects expected to be commercialised in the future at the new plant established at our site in Massachusetts, US. Demand for NittoPhase nucleic acid materials also increased for commercial drugs for certain customers.」
Production began at the new plant in Massachusetts, US, for projects expected to be commercialised in the future, while demand for NittoPhase for commercial drugs for certain customers also increased. - FY2024AdvancedAnnual report
「During the current consolidated fiscal year, we made capital investments totalling more than ¥30 billion in the US and Japan to meet demand for contract manufacturing in the nucleic acid drug market, where commercialisation of treatments for more patients than those with rare diseases is expected to advance, and a new plant with manufacturing capacity for commercial production began operations.」
In nucleic acid contract manufacturing, more than ¥30 billion was invested in the US and Japan, and the business reached the stage at which a new plant equipped for commercial production began operations. - FY2024-Q3RestatedAnnual report
「Meanwhile, with commercialisation for major diseases expected in the nucleic acid drug market, we began pilot production at the new plant established at our site in Massachusetts, US, to meet future demand growth.」
The start of pilot production at the new plant in Massachusetts, US, was reaffirmed. - FY2024-Q2AdvancedAnnual report
「In nucleic acid contract manufacturing, demand for nucleic acid adjuvants for vaccines declined as COVID-19 subsided. Meanwhile, with commercialisation for major diseases expected in the nucleic acid drug market, we began pilot production at the new plant established at our site in Massachusetts, US, to meet future demand growth.」
While the decline in demand for nucleic acid adjuvants for COVID-19 vaccines was noted, pilot production began at the new plant in Massachusetts, US, marking progress toward preparing for future demand in the nucleic acid drug market. - FY2024-Q1AdvancedAnnual report
「With commercialisation for major diseases expected in the nucleic acid drug market, a new plant was completed at our production site in Massachusetts, US, to meet future demand growth, and an opening ceremony was held.」
In preparation for increased demand for nucleic acid drugs, the new plant in Massachusetts, US, was completed and reached the stage of holding its opening ceremony. - FY2023AdvancedAnnual report
「To meet this expected growth in demand, a new plant being built at our site in Massachusetts, US, for the nucleic acid contract manufacturing business is scheduled for completion during the first half of fiscal 2023. A new plant for nucleic acid synthesis materials is also under construction at sites in Japan and California, US, with operations planned to begin from fiscal 2024 onward.」
For nucleic acid contract manufacturing, a new plant in Massachusetts, US, and for NittoPhase, new plants in Japan and California, US, were planned, giving concrete form to capacity expansion to meet rising demand. - FY2023-Q3Increased demand for nucleic acid contract manufacturing and NittoPhase, and suspension of orders for vaccine adjuvantsAnnual report
「Revenue in the Life Sciences business increased from the cumulative third quarter of the previous fiscal year. Against a backdrop of growth in the nucleic acid drug market, demand increased for nucleic acid contract manufacturing and NittoPhaseTM, a synthesis material used to manufacture nucleic acid drugs. Meanwhile, new orders for nucleic acid adjuvants for COVID-19 vaccines, whose demand had grown alongside the surge in COVID-19 infections, stopped from the second quarter due to the decline in global vaccination rates.」
While demand for nucleic acid contract manufacturing and NittoPhase increased, new orders for nucleic acid adjuvants for COVID-19 vaccines stopped from the second quarter due to the decline in vaccination rates. - FY2023-Q2RestatedAnnual report
「As COVID-19 vaccination progressed worldwide, nucleic acid adjuvants for COVID-19 vaccines grew in the nucleic acid contract manufacturing business. In addition, demand for NittoPhaseTM, a nucleic acid synthesis material, increased against a backdrop of growth in the nucleic acid drug market.」
Growth in nucleic acid adjuvants for COVID-19 vaccines and increased demand for NittoPhase were reaffirmed. - FY2023-Q1RestatedAnnual report
「As COVID-19 vaccination progressed worldwide, nucleic acid adjuvants for COVID-19 vaccines grew in the nucleic acid contract manufacturing business.」
Growth in nucleic acid adjuvants for COVID-19 vaccines was reaffirmed in the nucleic acid drug contract manufacturing business. - FY2022RestatedAnnual report
「While COVID-19 vaccines remain in short supply worldwide, development of new vaccines is accelerating. In nucleic acid drug contract manufacturing, our group began supplying nucleic acid adjuvants (nucleic acid immune enhancers) used in COVID-19 vaccines and added a new production line.」
The start of supplies of nucleic acid adjuvants for COVID-19 vaccines and the addition of a production line were reaffirmed as initiatives to expand the contract manufacturing business. - FY2022-Q3AdvancedAnnual report
「While COVID-19 vaccines remain in short supply worldwide, development of new vaccines is accelerating. In nucleic acid contract manufacturing, our group began supplying nucleic acid adjuvants (nucleic acid immune enhancers) used in COVID-19 vaccines and added a new production line. In addition, against a backdrop of market expansion, demand for NittoPhase polymer beads for nucleic acid synthesis increased and contributed to performance.」
In addition to beginning supplies of nucleic acid adjuvants for COVID-19 vaccines, we added a new production line, while increased demand for NittoPhase also contributed to performance. - FY2022-Q2AdvancedAnnual report
「While COVID-19 vaccines remain in short supply worldwide, development of new vaccines is accelerating. In nucleic acid contract manufacturing, our group began supplying nucleic acid adjuvants (nucleic acid immune enhancers) used in COVID-19 vaccines. In addition, against a backdrop of market expansion, demand for NittoPhaseTM polymer beads for nucleic acid synthesis increased and contributed to performance.」
We began supplying nucleic acid adjuvants for COVID-19 vaccines through our nucleic acid contract manufacturing business, and increased demand for NittoPhase reached the stage of contributing to performance. - FY2022-Q1AdvancedAnnual report
「In nucleic acid contract manufacturing, the response to clinical trials for COVID-19 vaccines began contributing to performance, and increased demand for NittoPhase, a nucleic acid synthesis material, also contributed to results.」
In nucleic acid drug contract manufacturing, the response to clinical trials for COVID-19 vaccines began contributing to performance, and demand for NittoPhase, a synthesis material, also increased. - FY2021Specific contract manufacturing initiativesAnnual report
「Against this backdrop, we aim to further expand earnings by increasing production capacity in the contract manufacturing business and expanding our design service capabilities for nucleic acid manufacturing processes, drawing on the expertise we have developed to date.」
For nucleic acid drug contract manufacturing, the company outlined initiatives to expand production capacity and, in addition, expand its design service capabilities for nucleic acid manufacturing processes. - FY2021-Q2RestatedAnnual report
「In the Life Sciences business, demand for nucleic acid drug contract manufacturing remained firm as the market grew. In addition, expectations for nucleic acid drugs as COVID-19 treatments and vaccines increased more than ever, and demand for NittoPhase polymer beads for nucleic acid synthesis expanded.」
Against a backdrop of growth in the nucleic acid drug market, demand for contract manufacturing remained firm, and the increase in demand for NittoPhase was reaffirmed. - FY2021-Q1AdvancedAnnual report
「Demand for nucleic acid drug contract manufacturing remained firm as the market grew. In addition, expectations for nucleic acid drugs as COVID-19 vaccines increased, and demand for NittoPhase polymer beads for nucleic acid synthesis expanded.」
Demand for nucleic acid drug contract manufacturing remained firm, and the disclosure also noted increased demand for NittoPhase polymer beads for nucleic acid synthesis. - FY2020RestatedAnnual report
「During the previous consolidated fiscal year, we recognized final revenue from nucleic acid drug contract manufacturing resulting from a customer's discontinuation of new drug development. As a result, business performance for the current consolidated fiscal year was below that of the same period of the previous year, but revenue is showing signs of recovery as we meet demand in the steadily growing nucleic acid drug market.」
The disclosure recognizes the impact from the customer's project discontinuation in the previous year while stating that contract manufacturing revenue is showing signs of recovery against a backdrop of growth in the nucleic acid drug market. - FY2020-Q3RestatedAnnual report
「In the consolidated accounting period corresponding to the first quarter of the previous fiscal year, we recognized final revenue from nucleic acid drug contract manufacturing resulting from a customer's discontinuation of new drug development. As a result, current-period performance was below that of the same period of the previous year, but revenue is showing signs of recovery as we meet demand in the steadily growing nucleic acid drug market.」
The disclosure reaffirmed that, although performance was below the same period of the previous year due to the rebound from final revenue recognized last year following the customer's discontinuation of new drug development, revenue from contract manufacturing is showing signs of recovery against a backdrop of growth in the nucleic acid drug market. - FY2020-Q2Rebound from last year's final revenue recognition and recovery in demandAnnual report
「In the consolidated accounting period corresponding to the first quarter of the previous fiscal year, we recognized final revenue from nucleic acid drug contract manufacturing resulting from a customer's discontinuation of new drug development. As a result, current-period performance was below that of the same period of the previous year, but demand for contract manufacturing is showing signs of recovery as the nucleic acid drug market grows.」
The disclosure states that current-period performance was below the same period of the previous year due to the rebound from final revenue recognized last year following the customer's discontinuation of new drug development, while demand for contract manufacturing is showing signs of recovery as the nucleic acid drug market grows. - FY2020-Q1RestatedAnnual report
「The nucleic acid drug market is growing due to an increase in new approvals, and demand for contract manufacturing is also increasing steadily.」
Although current-period performance was below the same period of the previous year due to the反動 from final revenue recognized in the same period last year, the growth of the nucleic acid drug market and the increase in demand for contract manufacturing were reaffirmed. - FY2019RestatedAnnual report
「In nucleic acid drug contract manufacturing, we were affected by changes in the customer's new drug development status during the previous consolidated fiscal year. However, development and clinical trials for new nucleic acid drugs have remained active, and contract manufacturing continues to trend upward.」
The disclosure notes the impact of changes in customer projects during the previous fiscal year while reaffirming the growing activity in nucleic acid drug development and clinical trials and the upward trend in contract manufacturing. - FY2019-Q2Half-year performance updateAnnual report
「In nucleic acid drug contract manufacturing, we were affected by changes in the customer's new drug development status and recognized the final revenue under the contract manufacturing agreement in the first quarter.」
The half-year report also states that final revenue was recognized in the first quarter for a contract manufacturing agreement affected by changes in the customer's new drug development status. - FY2019-Q1Performance update following the impact on contract manufacturingAnnual report
「In nucleic acid drug contract manufacturing, we were affected by changes in a customer's new drug development status in the previous fiscal year. Negotiations under the relevant contract manufacturing agreement have been completed, and final revenue was recognized in the first quarter of the current fiscal year.」
The disclosure states that negotiations were completed and final revenue was recognized for a contract manufacturing agreement affected in the previous fiscal year by changes in the customer's new drug development status. - FY2018WorsenedAnnual report
「In the Life Sciences business, earnings were affected by the discontinuation of a customer's new drug development in the nucleic acid drug contract manufacturing business.」
Due to the impact of a customer's discontinuation of new drug development, revenue from the Life Sciences business, including nucleic acid drug contract manufacturing, was ¥36,171 million and operating profit was ¥5,985 million, down 18.6% and 71.8%, respectively, year on year. - FY2018-Q3WorsenedAnnual report
「In the contract manufacturing business for nucleic acid drugs, which had driven segment earnings to date, some customers announced the cancellation of contract projects in late-stage clinical trials, and contract production for those customers, which had continued to increase, was abruptly halted.」
In nucleic acid drug contract manufacturing, contract production was abruptly halted following the cancellation of a late-stage clinical trial project by a major customer, worsening the business's earnings performance. - FY2018-Q2AdvancedAnnual report
「In the Life Sciences business, we added nucleic acid drug substance manufacturing equipment at our US contract manufacturing subsidiary, increasing its previous manufacturing capacity to more than double, and began operations in August. Although revenue increased year on year, profit growth was sluggish due in part to higher costs associated with this capacity expansion investment and pricing adjustments for certain projects.」
Equipment capable of more than doubling manufacturing capacity for nucleic acid drug contract manufacturing in the US began operations in August. However, profit growth was sluggish due to higher costs associated with the capacity expansion investment and pricing adjustments for certain projects. - FY2018-Q1AdvancedAnnual report
「In the North American contract manufacturing business for nucleic acid therapeutics, the company made an investment to more than double production capacity in order to further strengthen its market advantage as the industry leader.」
In North American contract manufacturing of nucleic acid drugs, we made an investment to more than double production capacity. This is a specific capacity expansion initiative aimed at maintaining and expanding our industry-leading market share. - FY2017AdvancedAnnual report
「In the Life Sciences business, the company aims for high growth by leveraging enhanced facilities and acquired services, expanding its value chain through M&A and increasing production capacity through capital investment, while maintaining a high industry share in contract manufacturing for nucleic acid therapeutics.」
The company has specified measures to expand its value chain through M&A and increase production capacity through capital investment, using the acquired analysis and aseptic filling services and enhanced facilities. - FY2017-Q3AdvancedAnnual report
「To further expand its nucleic acid therapeutics manufacturing business, which holds the industry's leading market share, the company acquired the assets of a pharmaceutical analysis services company and an aseptic filling services company in the United States and established a new company.」
In the contract manufacturing business for nucleic acid therapeutics, the company completed the asset acquisitions of a pharmaceutical analysis services company and an aseptic filling services company and established a new company. - FY2017-Q2AdvancedAnnual report
「Medical (healthcare-related materials) was driven by the smooth expansion of contract manufacturing by the U.S. nucleic acid therapeutics group company. In October, the company acquired the assets of 2 U.S. companies providing pharmaceutical analysis services and aseptic filling services. It aims to further expand the business by differentiating itself from competitors in the nucleic acid therapeutics market, which is expected to grow.」
The U.S. contract manufacturing business for nucleic acid therapeutics expanded, and the company also acquired the assets of 2 companies providing pharmaceutical analysis services and aseptic filling services. - FY2017-Q1AdvancedAnnual report
「Medical (healthcare-related materials) was driven by the smooth expansion of contract manufacturing by the U.S. nucleic acid therapeutics group company.」
The disclosure states that the U.S. contract manufacturing business for nucleic acid therapeutics expanded smoothly and drove performance in the Medical business. - FY2016First statedAnnual report
「As the development of nucleic acid therapeutics became increasingly active worldwide, demand for contract synthesis continued to rise. The company launched the business in Japan in addition to the United States and established a track record there.」
The company launched its contract synthesis business for nucleic acid therapeutics in Japan in addition to the United States.